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Introduction
Advancements in donor identification, experimental methods, and the generation of  better reagents for 
cloning pathogen-specific antibodies have been realized in the past decade (1–3). These innovations have 
led to rapid growth in the number of  broadly neutralizing antibodies (bnAbs) identified against clinically 
relevant pathogens, including HIV-1 (4–11). However, the ability to unambiguously translate binding to 
Major advances in donor identification, antigen probe design, and experimental methods to 
clone pathogen-specific antibodies have led to an exponential growth in the number of newly 
characterized broadly neutralizing antibodies (bnAbs) that recognize the HIV-1 envelope 
glycoprotein. Characterization of these bnAbs has defined new epitopes and novel modes of 
recognition that can result in potent neutralization of HIV-1. However, the translation of envelope 
recognition profiles in biophysical assays into an understanding of in vivo activity has lagged 
behind, and identification of subjects and mAbs with potent antiviral activity has remained reliant 
on empirical evaluation of neutralization potency and breadth. To begin to address this discrepancy 
between recombinant protein recognition and virus neutralization, we studied the fine epitope 
specificity of a panel of CD4-binding site (CD4bs) antibodies to define the molecular recognition 
features of functionally potent humoral responses targeting the HIV-1 envelope site bound by CD4. 
Whereas previous studies have used neutralization data and machine-learning methods to provide 
epitope maps, here, this approach was reversed, demonstrating that simple binding assays of fine 
epitope specificity can prospectively identify broadly neutralizing CD4bs–specific mAbs. Building 
on this result, we show that epitope mapping and prediction of neutralization breadth can also be 
accomplished in the assessment of polyclonal serum responses. Thus, this study identifies a set 
of CD4bs bnAb signature amino acid residues and demonstrates that sensitivity to mutations at 
signature positions is sufficient to predict neutralization breadth of polyclonal sera with a high 
degree of accuracy across cohorts and across clades.
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recombinant protein in biophysical assays into an understanding of  in vivo activity against HIV-1 has 
lagged behind. In particular, there is a lack of  concordance between antibody recognition of  recombi-
nant antigen in biophysical assays and broad antiviral neutralization activity in cell- and pseudovirus-based 
functional assays in the setting of  humoral responses to HIV-1 infection and vaccination. Consequently, 
identification of  subjects and mAbs with potent antiviral activity has generally remained reliant on empir-
ical evaluation of  neutralization potency and breadth. Such distinctions suggest that further work aimed 
at refining the properties of  the antigen-derived protein probes used to characterize binding patterns of  
humoral responses may contribute to more efficient and effective identification of  both protective mAbs 
and polyclonal antibody (pAb) responses.
HIV-1 bnAbs are of  high interest due to their ability to prevent infection in animal models (12–16) 
and influence viral loads and host responses in humans (17–21). Numerous such bnAbs have been isolated 
and mapped to different regions of  the HIV-1 spike, including the V1/V2 loop region, the V3 loop region, 
the membrane proximal extracellular region, the gp120-gp41 interface, and the CD4 receptor–binding site 
(CD4bs) (22–27). Among these, the CD4bs is of  particular interest as a target for both mAb therapy and 
prophylaxis as well as for vaccine design. Despite the high sequence variability of  the virus envelope, the 
CD4bs is functionally conserved and less masked by the glycan shield, and numerous potent bnAbs have 
been mapped to this region. Intriguingly, while many infected and vaccinated subjects raise CD4bs-spe-
cific antibodies, only a subset is broadly or potently neutralizing (28). Among these, convergent binding 
modes and common maturation pathways have been observed (29–31). Strikingly, differences in the angle 
of  approach of  broad or nonneutralizing CD4bs antibodies have been noted, as have differences in the fine 
epitope footprints (32, 33). Taken together, these findings suggest an association between CD4bs antibody 
fine epitopes and the ability to broadly and potently neutralize HIV-1.
Here, we undertook a study to evaluate the fine epitope specificity of  a panel of  CD4bs mAbs using a 
designed library of  YU2 gp120 core amino acid point mutants (34), and, in doing so, we define the molec-
ular recognition features of  functionally potent humoral responses to the HIV-1 envelope CD4bs. Whereas 
previous studies have used neutralization data to delineate antibody epitopes (35–40), here that process 
is reversed to allow prediction of  neutralization potency from epitope-mapping experiments. Employing 
both computational models and experimentation, we demonstrate that biophysical definition of  antibody 
fine epitope specificity can contribute to prospective identification of  broadly neutralizing CD4bs–specific 
mAbs. Building on this result, we further show that epitope mapping and predictions of  neutralization 
breadth can be accomplished in the setting of  polyclonal serum responses.
Results
Fine CD4bs epitope specificity predicts neutralization breadth. To define antibody epitopes, we mapped a set 
of  approximately 30 single amino acid substitution variants of  yeast-displayed YU2 gp120 core (34) via 
flow cytometry for disruption of  binding across a panel of  CD4bs antibodies. We evaluated 9 antibodies 
with narrow and/or weak neutralizing activity (wnAbs) (41), including b6 and F105; 6 vaccine-induced 
non-bnAbs from macaques (viAbs) (42); 9 antibodies with more broad and potent neutralization activity 
(bnAbs; b12, VRC01, PGV04, NIH45-46 G45W, CH31-CH34, and CH103); and the natural ligand CD4. 
This set of  CD4bs mAbs, as well as CD4, generally shared a common pattern of  sensitivity toward 4 
residues, K282, D368, G473, and R476, all located along the CD4bs ridge facing the inner core domain 
(representative examples, Figure 1A). However, hierarchical clustering demonstrated that the epitope maps 
of  CD4bs bnAbs could be differentiated from the non–broadly neutralizing (non-bnAb) CD4bs viAbs 
and wnAbs (Figure 1B), indicating a common difference in CD4bs recognition that was associated with 
neutralization breadth. The group of  clustered bnAbs was distinguished by sensitivity to point mutations 
deeper within the CD4bs (Figure 1A), associated with S365K, T455E, and G459E substitutions (Figure 
1B). Thus, both visual inspection and hierarchical clustering indicated that epitope maps could be used to 
discriminate neutralization breadth among CD4bs mAbs.
Validation of  bnAb epitope signatures to predict CD4bs antibody neutralization breadth. To further investigate 
this observation, a random forest model (43), which corrects for decision trees’ propensity to overfit data, 
was trained to classify the CD4bs mAbs by neutralization breadth (bnAb versus viAb and wnAbs) via the 
generation of  an ensemble of  decision trees, using epitope-mapping data as input. Perfect classification 
accuracy was achieved across the set of  mAbs in the setting of  leave-one-out cross-validation (Table 1). The 
relative importance of  each mutant in the panel to predictively classifying neutralization breadth across 
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the forest of  decision trees identified positions S365, G459, and T455 (Figure 2A) as contributing the most 
toward classifier predictions. As might be expected, the 10 mutated CD4bs residues were generally ranked 
higher than mutations at other positions in the gp120 core. The widely used CD4bs-defining D386R muta-
tion (44) ranked among the bottom half  of  variants, providing essentially no contribution to neutralization 
Figure 1. Epitope mapping of CD4bs antibodies. A panel of gp120 core point mutants was used to epitope map CD4bs antibodies (n = 25). Representative 
mAbs from 4 groups, including weakly neutralizing (wnAbs), vaccine-induced, and broadly neutralizing (bnAb) antibodies were evaluated. (A) The sensitiv-
ity of various mAbs to mutation of core residues is plotted on a structural representation. The CD4bs is colored green, and tolerated point mutations are 
colored black, while substitutions driving reduced (<80%; light blue to red) or strongly enhanced (>160%; blue) binding to the core relative to WT are indi-
cated. (B) Heatmap representation of the epitope-mapping results observed for the set of CD4bs mAbs. Hierarchical clustering identifies major subgroups 
of CD4bs mAbs that are associated with neutralization breadth and potency. The color bar at top indicates the class of core: core variants with substitu-
tions made in CD4bs residues are indicated in green, core variants with substitutions made in other sites on the core indicated are indicated in black, and 
the unmutated WT core are indicated in gray. The color bar at the left indicates the mAb class, with bnAbs indicated in black and non-bnAbs indicated in 
shades of gray (vaccine-induced antibodies in light gray, infection-induced antibodies in dark gray).
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breadth classification, which is consistent with the sensitivity of  all CD4bs mAbs tested to this mutation. 
Similar performance and contributing features were observed using elastic net classification as an alterna-
tive modeling approach, supporting the generalized ability of  this epitope recognition signature to predict 
neutralization breadth. Finally, permutation tests, in which models were learned from data when the neu-
tralization class labels had been scrambled, further established model robustness.
Based on these models, a triply mutated variant of  the gp120 core, denoted as STG and consist-
ing of  S365K, T455L, and G459E substitutions, was generated by site-directed mutagenesis in order 
to evaluate bnAb signature substitutions in combination. The sensitivity of  each CD4bs mAb to the 
substitutions present in the STG mutant and to the D368R substitution was evaluated relative to WT 
core. Whereas all CD4bs mAbs were sensitive to substitution at the D368 position, as evidenced by an 
average 75% decrease in binding signal for the D368R variant relative to WT core, only bnAb recogni-
tion was dramatically affected by the STG triple mutation (Figure 2B). While the D368R mutation did 
tend to be more disruptive to bnAbs than non-bnAbs, recognition by more than half  of  the non-bnAbs 
was reduced by a factor equivalent to that of  the bnAbs. In contrast, antibody binding to the STG 
mutant was generally unaffected for non-bnAbs, maintaining an average of  97% of  WT signal, whereas 
it was dramatically decreased among bnAbs, averaging 3% of  WT signal (P = 3.1 × 10–12 by 2-tailed 
Mann-Whitney test). Thus, consistent with the hierarchical clustering and random forest classification 
results, in which bnAbs and non-bnAbs could be discriminated statistically with the mutant panel using 
models weighted heavily on the 3-position signature, evaluation of  the STG triple mutant confirmed 
robust discrimination capacity experimentally. A limited set of  other substitutions was made at these 
positions and demonstrated similar binding profiles, indicating that bnAb sensitivity was likely more 
position rather than substitution specific.
Epitope mapping of  polyclonal sera. Based on excellent discrimination among mAbs, we next evaluated 
whether the mutant panel could be used to epitope map pAb samples derived from serum. A set of  121 
samples from chronically infected subjects from Boston area cohorts was screened for binding to yeast-dis-
played YU2 core, and the 99 samples with significant YU2 core reactivity were further evaluated across 
the entire mutant panel (Figure 3A). While essentially all serum samples with core-specific antibodies were 
highly sensitive to the D368R mutation and moderately sensitive to substitutions at G473 and R476, they 
did not bear appreciable sensitivity to the neutralization breadth signature residues. When clustered along-
side the maps from the CD4bs mAb panel (Figure 3A), the pAb-binding signatures were clearly more simi-
lar to the wnAbs and viAbs than the group of  bnAbs, which formed their own branch on the dendrogram. 
Indeed, because neutralizing responses were expected among chronically infected subjects (45), the lack of  
any CD4bs bnAb-like epitope signatures suggested that either the mAb-derived signature was not a general 
feature of  pAb responses or that more prevalent responses toward the lower CD4bs ridge might impede 
detection of  less common antibodies able to interact with the CD4bs neutralization signature residues.
To investigate the hypothesis that CD4bs non-bnAbs may mask the detection of  CD4bs bnAbs, serum 
from the CD4bs bnAb PGV04 donor was epitope mapped (Figure 3B). Indeed, despite the presence of  a 
bnAb, serum from the PGV04 donor failed to recapitulate characteristics of  the PGV04 mAb and appeared 
similar to the other serum samples evaluated: sensitivity to the bnAb signature residues was not observed, but 
reduced binding to D368R and R476V mutants was noted. Similar results were observed when known con-
centrations of  the PGV04 mAb were spiked into HIV immune globulin (HIVIG), confirming the hypothesis 
that nonneutralizing core-specific antibodies can impede detection of  bnAbs in mapping approaches that 
rely on the gp120 core. This observation suggested that depleting pAb samples of  non-bnAbs using the STG 
Table 1. Classification confusion matrix of mAb neutralization breadth
Predicted
Observed
bnAb Non-bnAb Classification error (%)
bnAb 10 0 0
Non-bnAb 0 15 0
A random forest classifier has been trained to classify mAb neutralization breadth using measured epitope maps. All mAbs were successfully classified in 
the setting of leave-one-out cross-validation.
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mutant might result in the enrichment of  CD4bs bnAbs. This possibility was experimentally tested by passing 
PGV04-spiked HIVIG through a spin column containing a bed of  STG-displaying yeast and epitope mapping 
the column flow through. Similar serum adsorption steps have contributed to previous gp120 epitope-mapping 
studies (46). This enrichment step enabled identification of  sensitivity toward substitution of  critical residues 
recognized by the PGV04 mAb, demonstrating that this flow-through fraction was enriched for antibodies 
with the PGV04 phenotype. Similarly, though insufficient PGV04 donor serum was available to evaluate the 
STG-enriched fraction against the whole epitope panel, a subset of  the panel was analyzed for binding to the 
enriched fraction. Sensitivity to S365K, T455E, G459E, I467K, and G473R, key features of  the PGV04 mAb 
that were not observed in whole PGV04 donor serum, was observed following enrichment (Figure 3B).
Inspired by the observation that STG-based enrichment could unmask the presence of  a CD4bs bnAb, 
we extended this enrichment process across a set of  10 serum samples from a Tanzanian cohort. In a pilot 
experiment, enriched sera (the flow-through fraction that results when the pool is depleted by passage 
through a column of  STG yeast cells) were analyzed for differential binding to a subset of  the mutant panel, 
and the majority of  these demonstrated differences in epitope-mapping results before and after enrichment 
(Figure 3C). The difference between before and after enrichment maps that was most apparent was increased 
sensitivity to K282V, S365K, and G473R substitutions. Limited sensitivity to T455E was noted, and none 
of  these samples demonstrated sensitivity to G459E. When the neutralization activity of  this limited panel 
Figure 2. Classification of 
CD4bs mAb neutralization 
breadth. (A) A random forest 
approach was used to classify 
mAb neutralization breadth 
using epitope maps. The 
relative importance of each 
point mutant to the classifi-
cation models is presented in 
decreasing order, as ranked 
based on mean decrease in 
Gini index. CD4bs residues are 
colored in green, and other core 
residues are colored black. A 
structural model of the core, 
denoting the locations of the 
top 3 positions (S365, T455, 
G459) utilized by the classifier 
in red, is shown. (B) Bench-
marking against D368R. The 
residues most important to 
the classifier were mutated to 
generate a triple mutant probe 
(STG). The binding of each 
CD4bs mAb (n = 26) relative to 
the WT gp120 core is presented 
for STG and the CD4bs probe 
D368R across individual mAbs 
and when grouped according 
to neutralization breadth. Data 
are represented as median and 
interquartile range.
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of  serum samples was determined, only weak and narrow responses were noted, consistent with the lack 
of  responses to the substitutions characteristic of  CD4bs bnAbs. While the Tanzanian serum samples were 
relatively insensitive to T455E and G459E, and were also nonneutralizing, suggesting the utility of  this 
mapping approach, we wished to more meaningfully explore the utility of  this epitope signature by applying 
it to samples with known neutralization profiles. To this end, we applied the enrichment process to a set of  
16 serum samples from the RV217 cohort that were known to be broadly neutralizing but for which epitope 
mapping based on neutralization data (40) suggested a wide range of  epitope specificities. As positive and 
negative controls, mock samples consisting of  VRC01, PGV04, or F105 mAbs spiked into HIVIG (5% by 
mass) were generated and subjected to the same enrichment process in parallel. Diverse titration patterns 
were observed across the set of  16 sera, with some subjects exhibiting depletion patterns similar to that of  
VRC01-spiked HIVIG and others more similar to the F105-spiked sample (Figure 4A). To quantitate these 
differences, the area under the titration curve (AUC) was calculated, and all samples were ranked by the 
ratio of  enriched WT-AUC over enriched STG-AUC (Figure 4B), as sera samples with a higher ratio would 
be predicted to be more likely to contain CD4bs bnAbs. Notably, among these samples, one subject demon-
strated a binding profile superior to that observed for either the VRC01 or PGV04 spike-in samples, and a 
number of  subjects exhibited profiles intermediate between these bnAbs and the F105-spiked sample. These 
results suggest the potential utility of  the STG mutant in B cell cloning and bnAb isolation efforts as well as 
in assessing bnAb prevalence more precisely in heterogeneous populations.
To link single substitution-level epitope maps of  enriched pAb fractions to pAb neutralization activity, 
samples with known neutralization potency from a second, independent Boston area cohort were evaluated. 
Figure 3. Polyclonal sera epitope-mapping results. (A) Heatmap comparing epitope-mapping data from polyclonal sera from Boston area (Ragon Institute) 
HIV-infected subjects positive for YU2 gp120 core-specific antibodies clustered together with the mAb epitope maps. The vertical color bar indicates sample 
type: pAb samples are shown in white (n = 99), bnAbs in black (n = 10), vaccine-induced weakly neutralizing antibodies (viAbs, n = 6) in light gray, and infec-
tion-induced weakly neutralizing antibodies (wnAbs, n = 9) in dark gray. (B) Serum from a donor with a known bnAb (PGV04) was evaluated for binding to 
the epitope-mapping panel. The ability of the STG mutant to deplete core-specific antibodies without broad neutralization and to facilitate identification of 
the presence of CD4bs antibodies with broad neutralization was determined for the PGV04 donor serum and for PGV04-spiked HIVIG. Error bars, shown only 
for the enriched PGV04 serum, indicate SD observed between duplicate measurements. (C) Heatmap of polyclonal sera samples from a Tanzanian cohort 
(n = 10) before and after enrichment of potential bnAbs using the STG mutant-based depletion. Horizontal color bars indicate the class of core: core variants 
with substitutions made in CD4bs residues are indicated in green, core variants with substitutions made in other sites on the core are indicated in black.
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Recognition profiles before (Figure 5A) and after (Figure 5B) CD4bs bnAb enrichment using the STG mutant 
were defined for a set of  10 serum samples. Clustering subjects based on the maps following enrichment iden-
tified a subset of  individuals with broad reactivity against the CD4bs, including sensitivities to bnAb signature 
residues that were only apparent following enrichment.
The neutralization potency of  these samples across a panel of  18 tier 2 viruses was tested (Figure 5C). 
Those samples that clustered together as being most strongly disrupted by CD4bs substitutions following 
STG-based enrichment exhibited potentiated neutralization capacity (as defined by the mean ID50 across 
the virus panel for each subject) relative to the cluster of  samples that were relatively insensitive to CD4bs 
substitutions (P < 0.01 by 2-tailed Mann-Whitney test).
Prediction of  serum neutralization breadth using the bnAb epitope signature. The presence of  the post hoc 
association described suggested that epitope maps following STG-based enrichment might support pre-
dictive models of  neutralization breadth in polyclonal samples. Therefore, we again utilized the random 
forest machine-learning method to train a classifier to distinguish neutralization breadth. We evaluated two 
cohorts, the 10 Boston area subjects described above and an additional cohort of  19 South African subjects 
to investigate whether this approach could be generalized to clade C infection. Predictions of  neutralization 
breadth class (high versus low) were made using all 31 mutations, the 10 CD4bs residues, or the 3 bnAb 
signature positions S, T, and G (Figure 5D and Table 2). Because the neutralization data for pAbs were 
collected from a limited panel of  pseudoviruses and for a limited number of  subjects, neutralization poten-
cy was divided into two groups: broadly neutralizing and non–broadly neutralizing, rather than across a 
continuum of  activities. As with any such classification exercise, results of  this analysis are expected to be 
somewhat dependent on the specific boundary used to define the two groups.
Permutation tests were conducted to evaluate the classification error distribution when neutralization class 
labels were scrambled. These tests established a baseline performance expectation that served as a negative 
control. When native serum maps were used, the performance of predictive models was essentially random, 
demonstrating accuracies of approximately 0.5 in defining the two classes. This performance was indistin-
guishable from the error distribution when permuted neutralization class assignments were predicted. In con-
trast, when the epitope-mapping data following the STG-based enrichment were used, all residue sets demon-
strated accuracies that were significantly better than predicted by chance alone (Table 2). Strikingly, the best 
predictive performance was observed when only the 3 bnAb signature positions were utilized (Figure 5D), 
Figure 4. Inferring the presence of CD4bs bnAbs via STG-based enrichment and serum profiling. A set of 16 samples from the RV217 HIV cohort were 
titrated for binding to WT (red) and STG (blue) core before and following enrichment of CD4bs bnAbs via STG-based depletion to enable inference of the 
presence or absence of CD4bs bnAbs. VRC01, PGV04, or F105 were spiked into HIV immune globulin (HIVIG) as positive and negative controls. (A) Titration 
curves of VRC01-spiked and F105-spiked HIVIG (top), and two RV217 subjects (bottom) before (broken line) and after (solid line) enrichment. The dotted 
line indicates the signal baseline used for AUC calculations. (B) The AUC for all sample titrations against WT and STG cores after enrichment was calcu-
lated and samples were plotted by rank in the ratio of the AUC for WT relative to STG. The mAb-spiked samples are highlighted in gray. Samples with no 
measurable binding were assigned a value of 100.
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demonstrating that this motif  was sufficient to effectively classify the breadth and potency of neutralization 
activity present. When these signature positions were excluded from consideration, model performance was 
significantly degraded, demonstrating that beyond being sufficient, these positions were also necessary for best 
results. Furthermore, both cohorts, which represent subjects infected primarily with either clade B or clade C 
viruses, demonstrated similar performance and reliance on the S, T, and G positions, suggesting that predictive 
models were neither cohort nor clade specific, but were generalizable. Indeed, when cohorts were combined, 
similar performance accuracy was observed, suggesting that similar decision trees effectively classified subjects 
from both cohorts. Collectively, these results suggest that STG-based enrichment was necessary, and that this 
enrichment approach was sufficient to enable prediction of neutralization breadth of polyclonal sera across 
cohorts and across clades with a high degree of accuracy.
Discussion
Considerable effort has been expended to identify and characterize antibodies with the ability to neu-
tralize diverse HIV-1 variants. Such bnAbs are not only potentially useful in prevention and treatment, 
but they also offer a model for vaccine design in that they encapsulate the natural developmental history 
and illuminate features of  potentially protective humoral immune responses. Since the first identifica-
tion of  HIV-1 bnAbs in the early 1990s, almost 100 bnAbs have been described (47), and a new wave 
of  clinical studies evaluating their utility has been initiated. In particular, a number of  CD4bs bnAbs 
Figure 5. Prediction of polyclonal sera neutralization breadth across diverse subject cohorts. Heatmap of the relative binding of sera before (A) and after 
(B) STG-based enrichment for a set of 10 samples from a second Boston area (BIDMC) cohort against CD4bs mutant cores (green), the WT core, and the triple 
mutant STG core (both in gray). (C) Neutralization potency (ID50) of the 10 sera samples across a panel of 18 tier 2 virus strains (each dot represents 1 unique 
virus strain) with subjects aligned as in A and B. Interquartile ranges and Tukey whiskers are shown; mean ID50 values across the virus panel for each subject 
were compared between the STG sensitive (green) and insensitive (black) group, with significance defined by Mann-Whitney test. (D) A classifier was trained 
to predict the neutralization breadth of polyclonal samples from HIV-infected subjects in the Boston area (BIDMC) cohort (n = 10), a South African cohort (n 
= 19), or both, based on epitope-mapping input of sera or the STG-enriched IgG fraction. Dashed lines represent classifier performance when the complete 
mutant panel (red), CD4bs residues only (green), or the S, T, and G positions alone (blue) were used in model training. Black lines represent classifier per-
formance when permuted neutralization class assignments were predicted using the whole panel or CD4bs and S, T, and G mutant subsets. Classification 
accuracy of models learned from considering S, T, and G positions only are noted at the top left of each panel in blue.
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are currently being investigated for antiviral therapy and prophylaxis (17–21). Similarly, diverse vaccine 
design strategies have focused on the CD4bs, involving approaches that have matured from obscuring 
other surface residues (48), to minimizing the presence of  other epitopes (49), to grafting the CD4bs 
onto alternative scaffolds (50), to designing modified CD4bs epitopes favoring interactions with specif-
ic germline B cell receptors (51), to selecting immunogens based on B cell and viral coevolution (52). 
These and other examples highlight the importance of  the CD4bs in the design of  both HIV-1 vaccines 
and antiviral antibody drugs.
The promising new work devoted to these efforts provides reason to be optimistic that eliciting 
CD4bs bnAbs by vaccination is possible and suggests that effective characterization of  the antibody 
responses being raised by novel vaccine candidates may serve a critical role in vaccine research and 
development. While other antibody phenotypes, such as loop length and CDR composition, have been 
used as surrogates to suggest progress toward neutralization breadth, such proxies are unlikely to be 
either strongly or universally associated with neutralization. Similarly, given the insufficiency of  CD4 
or antibody competition experiments to fully reflect neutralization potency, we expect that more sophis-
ticated epitope-mapping probes and strategies, such as that defined here, may be central to ongoing 
efforts to profile mAbs and pAb responses (53, 54). These methods may help in particular by providing 
more fine-grained information about modes of  recognition that may then better inform the design of  
future immunogens or immunization sequencing regimens.
Here, we show that prior knowledge as to function-phenotype linkages can be used to develop robust-
ly predictive models of  the neutralization phenotype observed for samples based on antigen recognition 
profiles. While inferences of  neutralization potency made from patterns of  binding recognition learned 
from examples could likewise be made from epitope information gained from other experimental meth-
ods, such as cocrystallization, hydrogen-deuterium exchange mass spectrometry, and scanning and shot-
gun mutagenesis, the yeast display-based approach has considerable experimental advantages. Similarly, as 
appropriate sets of  antibodies become available, defined antigen variants could be developed to distinguish 
neutralization breadth and potency at other epitopes of  interest.
Whereas the current state of  the art in pAb epitope mapping involves using experimental neutral-
ization data to predict HIV-1 antibody epitopes (35–39), here the directionality of  inference is reversed, 
and, to our best knowledge, this is the first time that polyclonal HIV-1 antibody epitope-mapping data 
were used to predict neutralization potency. While numerous laboratories have established high-through-
put means to conduct neutralization assays, biophysical probes bear advantages in cost, ease, and safety 
(55). Significantly, distillation of  a panel of  single amino acid point mutants into a single, triply mutated 
variant enabled highly efficient experimental discrimination by simply evaluating binding to WT versus 
triple mutant core. Collectively, these data also suggest that B cell sorting of  B cell receptors that prefer 
WT to the STG mutant could contribute to efforts to identify and clone CD4bs bnAbs.
However, generalization of  this epitope-based approach to deduce neutralization has a number of  lim-
itations. First, it relies on the availability of  antibodies with known activity profiles and thus has little 
relevance to settings in which such rich knowledge does not yet exist. Second, since it is built on prior 
knowledge, it is expected to have a limited ability to identify antibodies with novel recognition modes. If  
Table 2. Classification model accuracies
Permuted accuracy 
mean ± SD
Actual accuracy 
(%)
Prediction significance False positive/false negative rate 
(%)
mAb panel 50.3% ± 11.2% 100% A 0%/0%
Boston (BIDMC) cohort (S, T, G) 45.0% ± 19.2% 100% B 0%/0%
South African cohort (S, T, G) 57.8% ± 10.4%  84.2% B 15.8%/0%
Both cohorts (S, T, G) 50.0% ± 11.1%  89.7% A 6.9%/3.4%
Performance of epitope-mapping data for prediction of neutralization class based on permuted and actual class labels. False positives were defined 
as non–broadly neutralizing samples misclassified as broadly neutralizing samples; false negatives were defined as broadly neutralizing samples 
misclassified as non–broadly neutralizing samples. Prediction quality is indicated with respect to the difference between predictions of actual and 
permuted class assignments, where significance is represented as follows: Aprediction accuracy is 3 SD away from the permutation mean (accuracy > mean 
+ 3 SD); Baccuracy > mean + 2 SD.
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there are no examples in the class of  antibodies used to train models and build a discriminatory epitope 
probe, the designed probe will presumably have no ability to recognize new antibodies that may exhibit the 
same functional phenotype but rely on a different biophysical one.
We also note that while the STG probe was effective in distinguishing neutralization potency among 
mAbs and for the cohorts (Beth Israel Deaconess Medical Center [BIDMC] and South Africa) in which 
neutralization data were available, additional data are needed to further validate these observations. Rel-
evant to this concern, epitope maps (before and/or after enrichment) from other cohorts (Ragon Institute 
and Tanzania) differed from those observed among subjects for which neutralization data were available in 
several ways. For example, prior to enrichment, D368R was strongly disruptive in the majority of  subjects 
from the Ragon Institute cohort; this phenotype was considerably less prevalent among the BIDMC (and 
Tanzanian) subjects. Additionally, after enrichment, the BIDMC cohort samples with broad neutralization 
potency exhibited multiple sites of  substitution sensitivity, and this broad pattern of  disruption across the 
CD4bs was distinct from that observed among Tanzanian subjects after enrichment. Such differences in 
both the before and after enrichment epitope maps among the samples from which neutralization data were 
available could be potentially explained by a number of  factors, including time since infection, concomitant 
disease burdens, or differences in recognition of  YU2 core associated with diversity in the infecting virus, 
among others. By extension, we cannot exclude that other factors such as these may influence the utility of  
this approach to predict neutralization activity.
Our results also suggest that, in general, the bulk of  the antibody response in infected subjects that 
recognizes the gp120 core may not be relevant to virus neutralization. Indeed, it has long been known 
that much of  the humoral response to HIV-1 infection is directed to “viral debris” (56). Our observation 
that non-bnAb responses can mask the presence of  bnAbs has several important potential biological 
implications. First, this result is consistent with numerous previous studies reporting the inability of  
gp120-binding titers to strongly correlate with neutralization breadth and potency and with reports of  
limited success in isolating gp120-reactive antibodies with potent neutralizing activity (32, 57). That 
most core-specific antibody responses are apparently irrelevant to neutralization has implications as 
to the usefulness of  gp120 or gp120 cores as vaccine immunogens. This observation also suggests that 
there could be competition between neutralizing core-specific antibodies and nonneutralizing core-spe-
cific antibodies and that binding of  non-bnAbs might block bnAb activity. While we did not evaluate 
this possibility intensively, the inability of  non-bnAbs to compete with nAbs has been long established 
(58). Further, in this study, neutralization enhancement was not observed when a subset of  sera was 
evaluated for neutralization activity before and after STG-based depletion of  non-bnAbs. Finally, and 
in contrast to our biophysical assays, the presence of  PGV04 in the PGV04 donor serum was readily 
apparent in neutralization assays. Thus, these results indicate that, while non-bnAbs can mask biophys-
ical detection of  bnAbs, they likely do not mask bnAb neutralization activity either in vitro or in vivo. 
Finally, and perhaps surprisingly, we could observe good predictions based on assessment of  core-bind-
ing profiles alone. This result suggests that CD4bs-specific antibodies may represent a dominant mode 
of  neutralization or that they are correlated with the induction of  bnAbs directed at other sites, at least 
among the samples evaluated here.
Overall, this study demonstrates that antibody fine epitope specificity can serve as a powerful tool in 
neutralization breadth prediction for both mAbs and polyclonal sera. We envision that the application of  
this method to additional panels of  antibodies and antigen variants may bring more insights into future 
vaccine design against HIV-1 as well as other viruses and that the STG probe in particular may prove useful 
in ongoing efforts to evaluate humoral responses to candidate vaccines and to identification and cloning of  
novel bnAbs of  the CD4bs class.
Methods
mAbs. Six viAbs, including GE121, GE125, GE136, GE137, GE143, and GE148, were sourced from the 
Karolinska Institute (42). Seven narrowly and/or weakly neutralizing antibodies, including 448D, 559-
64D, 654-30D, 1008-30D, 1202-30D, and 1263D, were sourced from the NYU School of  Medicine (41). 
Five antibodies, including F105, b12, VRC01, and NIH45-46 G45W, were acquired from the NIH AIDS 
Reagent Program. Six antibodies, including CH31, CH32, CH33, CH34, CH98, and CH103, were pro-
vided by the Duke Human Vaccine Institute. The remaining CD4bs mAbs were provided by The Scripps 
Research Institute. The same set of  mAbs was used in Figure 1, Figure 2, and Figure 3A.
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Clinical samples. Serum samples from 176 HIV-infected subjects from cohorts, including chronically 
infected individuals from cohorts established by the Ragon Institute (n = 121); chronically infected individ-
uals from the greater Boston area (n = 10) available from BIDMC; antiretroviral drug-naive HIV-1 clade C 
chronically infected individuals from the Southern African National Blood services (n = 19); individuals 
subsequently purified for immunoglobulin at the DarDar Study in Dar es Salaam, Tanzania (n = 10) (59); 
and the RV217 early capture HIV cohort study (n = 16) (ECHO) collected 1–3 years after infection and prior 
to ART (60) were evaluated. Cohorts were not controlled for variation in viral load, CD4 count, time from 
infection, ART therapy, age, sex, or other factors that may influence antibody responses. IgG present in sera 
from HIV-infected donors was purified using Pierce Melon Gel according the manufacturer’s instructions. 
A 5% Triton X-100 solution in PBS was used to bring each sample to 0.5% Triton X-100 before heating 
at 37°C for 1 hour to inactivate virus. Neutralization activity for the Boston and African sample sets was 
determined using the TZM.bl assay across an 18-virus panel as previously described (61). Neutralization 
class identity was determined by mean value of  log-transformed ID50 across the panel of  HIV-1 strains.
Epitope mapping. A panel of  gp120 core mutants was induced and displayed on Saccharomyces cerevisiae 
strain EBY100 as previously described (34, 62). Amino acid substitutions S365K, T455L, and G459E were 
sequentially introduced using site-directed mutagenesis and confirmed by sequencing. Titrations were per-
formed for each antibody sample in order to determine, first, whether a YU2 core-specific response was 
present and, second, to identify the dose-response inflection point. The concentration at which signal is 
half-maximal represents an optimal concentration for epitope mapping, at which binding to the core was 
most sensitive to concentration and good signal to noise resolution is observed. For both titrations and 
epitope maps, approximately 1 × 105 yeasts displaying wild-type gp120 4G core were combined with 200 μl 
PBS + 0.1% BSA (PBSB) per well and centrifuged in 96-well plates at 3,200 g for 4 minutes. Supernatants 
were removed by aspiration, and cells were resuspended in 50 μl antibody solution containing titrations of  
mAbs or polyclonal sera and 1:400 mouse anti-HA tag antibody (Covance) and incubated with shaking 
for 1 hour at room temperature for mAbs or overnight at 4°C for human sera. Yeasts were washed twice 
with PBSB and stained for 20 minutes at room temperature with a 1:200 solution of  fluorescent goat anti-
mouse and anti-human/rhesus antibodies (1:200 each) to enable detection of  surface displayed core and 
bound core-specific antibody, respectively. Plates were washed and resuspended in 200 μl PBSB, and data 
were acquired on a MACSQuant Analyzer (Miltenyi Biotec). The mean fluorescent intensity (MFI) of  
gp120 core-displayed yeast was determined by gating on the HA tag-positive cells, and normalized MFIs 
were determined by determining the ratio of  test antibody signal relative to the level of  core display (test 
antibody MFI/HA tag MFI). Assays were generally performed in singlicate, as variability in the epitope 
mapping assay was previously evaluated, and found to exhibit an inter-study coefficient of  variation (%CV) 
of  generally less than 10% and intra-study %CVs under 5% (53, 54).
bnAb enrichment. The STG-based bnAb enrichments were performed by depleting polyclonal pools of  
core-specific antibodies that recognized epitopes other than the 3-residue bnAb signature. Briefly, approx-
imately 1.4 × 109 yeasts were washed with PBS before being gently pelleted for 2 minutes at 500 g in a 
cellulose acetate filter column (Pierce). A small volume of  PBS was added without disturbing the pellet, 
and a 30-μm polyethylene filter was placed on top of  the pellet as a frit (Pierce). PBS was removed from 
above the frit, and pAb sample was added to the column and centrifuged until the solution passed through 
the column at 250 g (approximately 15 minutes). The flow through was collected and reapplied to the col-
umn and centrifugation repeated at 500 g for approximately 10 minutes. This process was repeated on a 
total of  3 yeast-based affinity columns to ensure complete depletion. Enriched pAbs were either evaluated 
by epitope mapping using the yeast-displayed core mutants as described above or evaluated by assessing 
binding to STG and WT-conjugated fluorescently coded magnetic beads. Soluble STG gp120 core and WT 
gp120 core protein were expressed by HEK cells (Invitrogen) and purified using standard Ni-NTA chro-
matography. STG gp120 and WT gp120 proteins were then conjugated to the magnetic beads via primary 
amines through the NHS-EDC chemistry, as previously described (63, 64). To detect pAb bound to STG/
WT gp120, 30 μl enriched and unenriched pAbs were serially diluted in black, clear-bottom 384-well plates 
(Greiner Bio One) with a dilution factor of  4. For each specificity (STG and WT), 500 beads were added in 
a 20-μl volume to each well, followed by 1-hour incubation on a plate shaker at 1,050 rpm at room tempera-
ture. Plates were then washed with PBS with 1% BSA and 0.05% Tween and incubated in 50 μl anti-human 
IgG Fc-PE (Southern Biotech) at 650 ng/ml as a secondary antibody to detect bound pAbs for 30 minutes. 
Finally, plates were washed and beads were resuspended in 35 μl Luminex sheath fluid buffer. The net MFI 
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was detected and reported by a FlexMap 3D (Luminex, Bio-Plex Manger 5.0, Bio-Rad). Area under the 
curve was calculated in GraphPad Prism.
Data analysis and visualization. Surface representations of YU2 gp120 core mutants and mapped epitopes 
were generated using PyMOL and were colored based on a modeled gp120 core structure as described previ-
ously (34). Heatmaps were plotted by the gplots package in R.3.1.0 with the heatmap.2 function and dendro-
grams were generated by hierarchical clustering (Euclidean distance). Classification models were built using 
the random forest decision tree package “randomForest” in R.3.1.0 (43). 20,000 decision trees were built for 
each binomial trainer per run. The relative importance of each epitope-mapping measurement to classification 
models was evaluated by the mean decrease in Gini index. Predictive accuracy was assessed by leave-one-out 
cross-validation. Model quality was also assessed by permutation tests, in which neutralization class identity 
was randomized with a fixed ratio between bnAbs and nnAbs and the classifier performance was evaluated 
over 1,000 different permutations. Classification models with accuracies greater than 2 SDs above than the 
permuted model mean were regarded as significant. As methodological alternatives, elastic net models were 
also built using the Glmnet package (65), with an elastic net mixing parameter at 0.4, and use of leave-one-out 
cross-validation to determine the value of the tuning parameter lambda, such that minimum cross-validated 
mis-classification error was observed. Similar classification performance and common contributing features 
were observed across random forest and elastic net methods. Results from random forest models were selected 
for presentation, as this method is robust to outliers, computationally efficient, and resistant to overfitting (66).
Statistics. Subjects were clustered into groups defined by CD4bs epitope-mapping data, and the medi-
an neutralization ID50 values observed for individuals from each group were compared. A P value of  less 
than 0.01 was considered significant. Classification models were considered to perform significantly better 
than expected at random if  their accuracies were greater than 2 SDs above the mean accuracy observed 
from models learned from permuted data. Comparison of  neutralization ID50 values was conducted by 
Mann-Whitney test in R 3.3.1 with the wilcox.test function.
Study approval. All subjects were adults, and they provided written informed consent. The Dartmouth 
College Committee for the Protection of  Human Subjects approved the study.
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